Federal Register: December 28, 2004 (Volume 69, Number 248)
DOCID: FR Doc 04-28312
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NOTICE: NOTICES
ACTION: Meetings:
SUBJECT CATEGORY:
National Cancer Institute; Notice of Closed Meeting
DOCUMENT SUMMARY:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as [[Page 77759]]
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets of commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel SBIR Topic 206: Methods of Innovative Pharmaceutical Manufacturing & Quality Assurance.
Date: February 16, 2005.
Time: 12 p.m. to 4:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6130 Executive Blvd., Rockville, MD 20852, (Telephone conference call).
Contact Person: Kenneth L. Bielat, PhD, Scientific Review
Administrator, Division of Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116 Executive Boulevard,
Room 7147, Bethesda, MD 20892, (301) 4967576, bielatk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS.)
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0428312 Filed 122704; 8:45 am]
BILLING CODE 414001M
SUMMARY:
National Cancer Institute,
DOCUMENT BODY 2:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as [[Page 77759]]
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets of commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel SBIR Topic 206: Methods of Innovative Pharmaceutical Manufacturing & Quality Assurance.
Date: February 16, 2005.
Time: 12 p.m. to 4:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6130 Executive Blvd., Rockville, MD 20852, (Telephone conference call).
Contact Person: Kenneth L. Bielat, PhD, Scientific Review
Administrator, Division of Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116 Executive Boulevard,
Room 7147, Bethesda, MD 20892, (301) 4967576, bielatk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS.)
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0428312 Filed 122704; 8:45 am]
BILLING CODE 414001M